Use of valid diagnostic criteria is extremely important in the recognition of Alzheimer’s disease (AD).
Patients with mild to moderate Alzheimer’s disease should be started on a cholinesterase inhibitor and possibly anti-inflammatory agents, antioxidants (vitamin E or selegiline), and estrogen replacement therapy (for postmenopausal women). Close follow-up of functioning is needed to be able to provide symptomatic relief and possibly slow down the progression of the disease .
Comorbid medical conditions as well as superimposed psychiatric disturbances should be aggressively treated.
Pharmacologic interventions and environmental engineering (including support for family members) should be used throughout the course of the disease.
Genetic testing is not recommended in asymptomatic family members , considering the enormous potential for job and insurance discrimination.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 7.Small GW, Rabins PV, Bary PP, et al.: Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA 1997, 278:1363–1371. These comprehensive guidelines review the global treatment of Alzheimer’s disease.PubMedCrossRefGoogle Scholar
- 8.American Psychiatric Association: Practice guidelines for the treatment of patients with Alzheimer’s disease and other dementias of late life. Am J Psychiatry 1997, 154 (suppl 5):1–39. These comprehensive guidelines review the global treatment of Alzheimer’s disease.Google Scholar
- 11.Schneider LS, Farlow MR: Predicting response to cholinesterase inhibitors in Alzheimer’s disease: possible approaches. CNS Drugs 1995, 4:114–124.Google Scholar
- 12.Shintani EY, Uchida KM, et al.: Donepezil: an anticholinesterase inhibitor for Alzheimer’s disease. Am J Health Syst Pharm 1998, 54(24):2805–2810.Google Scholar
- 13.Rogers SL, Doody R, Mohs R, et al.: E2020 produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer’s disease: results of a 30-week phase III trial. Neurology 1996, 46:A217. This randomized double-blind placebo-controlled trial shows donepezil’s effect as a cognitive enhancer.Google Scholar
- 15.Pettenati C, Donato MF: Behavioral Symptoms of Alzheimer’s Disease: Improvement by Donepezil. Amsterdam: Sixth International Conference on Alzheimer’s Disease and Related Disorders; 1998.Google Scholar
- 16.Hausserman P, Reinbold H, Schroder SG: Benefit of Cognition Enhancers on Noncognitive Features of Dementia. Amsterdam: Sixth International Conference on Alzheimer’s Disease and Related Disorders; 1998.Google Scholar
- 26.Bores GM, Huger FP, Petko W, et al.: Pharmacological evaluation of novel Alzheimer’s disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1998, 277(2):728–738.Google Scholar
- 27.Parys W, Pontecorvo MJ: Treatment of Alzheimer’s Disease with Galanthamine, a Compound with a Dual Mechanism of Action. Amsterdam: Sixth International Conference on Alzheimer’s Disease and Related Disorders; 1998. This randomized double-blind placebo-controlled trial shows galanthamine’s effect as a cognitive enhancer.Google Scholar
- 28.Becker RE, Colliver JA, Markwell SJ, et al.: Double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease. Alzheimer Dis Assoc Disord 1996, 10(3):124–131. This randomized double-blind placebo-controlled trial shows metrifonate’s effect as a cognitive enhancer.PubMedGoogle Scholar
- 29.Cummings J, Bieber F, Mas J, et al.: Metrifonate in Alzheimer’s disease: results of a dose-finding study. Alzheimer Dis Assoc Disord 1996, 17(54):S153-S154.Google Scholar
- 33.Cutler NR, Jhee SS, Cyrus P, et al.: Safety and tolerability of metrifonate in patients with Alzheimer’s disease: results of a maximum tolerated dose study. Calif Clin Trials 1998, 62(16):1433–1441.Google Scholar
- 35.Anand R, Gharabawi G: Efficacy and safety results of the early phase studies with Exelon (ENA 713) in Alzheimer’s disease: an overview. J Drug Develop Clin Practice 1996, 8:1–14. This randomized double-blind placebo-controlled trial shows rivastigmine’s effect as a cognitive enhancer.Google Scholar
- 40.Schweitzer E, Rickels K, Hassman H, et al.: Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry 1998, 59(4):175–183.Google Scholar
- 43.Katz I, Brecher M, Clyde C, et al.: Risperidone in the Treatment of Psychosis and Aggressive Behavior in Patients with Dementia. Kamuela, HI: Thirty-sixth Annual Meeting of the American College of Neuropsychopharmacology; 1997.Google Scholar
- 44.Cantillon M, Brunswick R, Molina D, et al.: Buspirone vs haloperidol—a double-blind trial for agitation in a nursing home population with Alzheimer disease. Am J Geriatr Psychiatry 1996, 4:263–267.Google Scholar
- 47.Sultzer D, Gray KF, Gunay I: A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psych 1997, 5:60–69.Google Scholar
- 51.Marin D: Principles of pharmacotherapy of dementia. In Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ, Bunney BS. New York: Oxford University Press; 1999.Google Scholar
- 52.Samuels SC, Davis KL: Future therapeutic approaches to Alzheimer’s disease. J Clin Psychiatry 1998, 59(suppl 11):14–16.Google Scholar
- 56.Ashtana S, Baker LD, Craft S, et al.: Estrogen-Induced Enhancement in Memory in Postmenopausal Women with Alzheimer’s Disease. Amsterdam: Sixth International Conference on Alzheimer’s Disease and Related Disorders; 1998.Google Scholar
- 58.Riekkinen PJ: Review on the Long-Term Efficacy and Safety of Selegiline in the Treatment of Alzheimer’s Disease. Amsterdam: Sixth International Conference on Alzheimer’s Disease and Related Disorders; 1998.Google Scholar
- 64.Aisen PS, Altsteil L, Marin D, et al.: Treatment of Alzheimer’s disease with prednisone: results of pilot studies and design of multi center trial [abstract]. J Am Geriatr Soc 1995, 43:SA27.Google Scholar